CHEK1 and breast carcinoma: The efficacy of CHK1 inhibitor monotherapy or combination therapy with CHK1 inhibitors and cisplatin or docetaxel has been explored in clinical trials with enrolled patients with advanced solid tumors, breast cancer, and ovarian cancer [25,35].